902156-99-4

• 常用中文名：NVP-LCQ195
• 常用英文名：NVP-LCQ195
• CAS号：902156-99-4
• 分子式：C₁₇H₁₉Cl₂N₅O₄S
• 分子量：460.33500
• 相关类别： 研究领域 癌症
• 发布时间：2016-11-28 02:12:13
• 更新时间：2026-07-14 19:23:19
• NVP-LCQ195 (AT9311; LCQ195)是CDK杂环类抑制剂,对CDK1,CDK2,CDK3和CDK5的IC50为1-42 nM。

名称

• 中文名: NVP-LCQ195
• 英文名: 4-[(2,6-dichlorobenzoyl)amino]-N-(1-methylsulfonylpiperidin-4-yl)-1H-pyrazole-5-carboxamide
• 中文别名: 4-(2,6-二氯苯甲酰基氨基)-1H-吡唑-3-羧酸 N-[1-(甲基磺酰基)哌啶-4-基]酰胺; CDK杂环类抑制剂(NVP-LCQ195); 4-[(2,6-二氯苯甲酰基)氨基]-N-[1-(甲基磺酰基)-4-哌啶基]-1H-吡唑-3-甲酰胺; NVP-LCQ195 抑制剂; 4-(2,6-二氯苯甲酰胺基)-N-(1-(甲磺酰基)哌啶-4-基)-1H-吡唑-5-甲酰胺; NVP-LCQ195,CDK杂环类抑制剂
• 英文别名: LCQ-195; 4-(2,6-Dichlorobenzamido)-N-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazole-3-cboxamide; NVP LCQ195; NVP-LCQ195,AT-9311,NVPLCQ195,NVP-LCQ-195,inhibit,Cyclin dendent kinase,Inhibitor,AT 9311,NVP LCQ195,LCQ195,CDK,LCQ; AT 9311; NVP-LCQ195;LCQ-195;AT-9311;NVP LCQ195; 4-[(2,6-dichlorobenzoyl)amino]-N-(1-methylsulfonylpiperidin-4-yl)-1H-pyrazole-5-cboxamide; AT-9311; LCQ 195; CS-0840; 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-cboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide; NVP-LCQ195, 10 mM in DMSO; 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)amide; NVP-LCQ195 (AT9311; LCQ195); 4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-cboxylic acid N-[1-(methylsulfonyl)piperidin-4-yl]amide; LCQ-195;AT-9311;NVP LCQ195;LCQ 195;AT9311;AT; 1H-Pyrazole-3-cboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-[1-(methylsulfonyl)-4-piperidinyl]; NVP-LCQ195 (AT9311

物化性质

• 分子式: C₁₇H₁₉Cl₂N₅O₄S
• 分子量: 460.33500
• 精确质量: 459.05300
• PSA: 136.13000
• LogP: 3.91620
• 储存条件: -20°C

生物活性

• 描述: NVP-LCQ195 (AT9311; LCQ195)是CDK杂环类抑制剂,对CDK1,CDK2,CDK3和CDK5的IC50为1-42 nM。
• 相关类别:
  研究领域 >> 癌症
• 靶点:

  Cdk5/p25:1 nM (IC50)

  CDK5/p35:1 nM (IC50)

  Cdk1/cyclin B:2 nM (IC50)

  cdk2/cyclin A:2 nM (IC50)

  CDK2/cyclinE:5 nM (IC50)

  CDK9/cyclinT1:15 nM (IC50)

  CDK3/Cyclin E:42 nM (IC50)

  cdk6/cyclin D3:187 nM (IC50)

  CDK7/Cyclin H/MAT1:3564 nM (IC50)

• 参考文献:

  [1]. McMillin DW, Delmore J, Negri J et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb;152(4):420-32.

合成路线

124-63-0 ~93% 902156-99-4

文献：ASTEX THERAPEUTICS LIMITED Patent: WO2008/1101 A2, 2008 ; Location in patent: Page/Page column 366-367 ;

902152-86-7 4659-45-4 ~% 902156-99-4

文献：ASTEX THERAPEUTICS LIMITED Patent: WO2008/1101 A2, 2008 ; Location in patent: Page/Page column 369-370 ;

825619-04-3 741713-99-5 ~49% 902156-99-4

文献：ASTEX THERAPEUTICS LIMITED Patent: WO2007/129066 A1, 2007 ; Location in patent: Page/Page column 97-98 ;